SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

MORE HEADLINES

» Markets | Economy | Companies

- Health Care Bill Clears First Senate Hurdle

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Aug.18

11:50 AM ET

Monday, 18 Aug 2008

Former ImClone CEO Sam Waksal: He's Baaaack!

Posted By:Mike Huckman

Topics:Stock Market | Mergers & Acquisitions | CEOs and CFOs | Pharmaceuticals

Sectors:Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:ImClone Systems Inc. | Bristol-Myers Squibb Co

Sam Waksal
AP
Sam Waksal, former CEO of ImClone Systems
Late last week I blogged that ImClone Systems founder and former CEO Sam Waksal was, according to a source, going to get out of a federal prison in Michigan and move into a halfway house in the Bronx between August 7th and the 14th.

I was beginning to think it wasn't gonna happen in that time frame, but then late yesterday CNBC got confirmation from the Federal Bureau of Prisons that he'd indeed left the Milan facility for the new place in New York where he will presumably stay until his sentence is up early next year.
In the meantime, I guess, he can watch and read about the IMCL [IMCL Loading... () ]

takeover battle with Bristol-Myers Squibb[BMY Loading... () ]. Carl Icahn's latest investment disclosure statement filed with the SEC yesterday doesn't show any change in the size of his ImClone holding.

I'm not sure what life in a Bronx halfway house is like. My biological mother served a few months in a Cleveland halfway house in the 1990s, but she didn't want me to visit. Her reason for being there is no secret since her story was featured on "60 Minutes" several years ago.

Quick back story. After we were reunited (I was adopted) she fell into a career helping other adoptees and bioparents find each other. But the feds nabbed her for posing as other people on the phone to get identifying information for her clients.

ImClone Hires JPMorgan to Weigh Options

Misrepresenting myself is something I wouldn't do as a reporter/journalist. I'm not gonna sneak into the Bronx halfway house posing as a visitor in order to try to get to see Sam. As I think any of my professional contacts will tell you, I am always right up front and direct about what I'm after.

So, Sam Waksal, if you're reading this, consider it a request for an exclusive interview.

Questions? Comments?

Tools:

Print Email